Articles from Pathway to Cures

Fifth paragraph of release dated November 19, 2025, should read: Pathway to Cures joins Hextwo Capital as early investors in SeraGene Therapeutics.

Pathway to Cures (P2C) congratulates Dr. Navid Khodaparast, PhD, co-founder and CSO of P2C portfolio company Spark Biomedical, as a Wellcome Leap awardee of “The Missed Vital Sign” worldwide program. This Wellcome Leap program addresses unmet needs in heavy menstrual bleeding with a goal of reducing the time it takes a woman to get effective treatment for heavy menstrual bleeding more than tenfold – from 5 years to 5 months.

Pathway to Cures (P2C) announced their annual fund update meeting on Wednesday, September 11th in Atlanta, Georgia.

Pathway to Cures (P2C) announces two new members to its board of directors, Sharon Richardson, PhD, a Director on the National Bleeding Disorders Foundation Board, and Philip M. Gattone, M.Ed., President and CEO of the National Bleeding Disorders Foundation.

Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D. Dr. Valentino most recently served as President and CEO of the National Bleeding Disorders Foundation (NBDF) and was instrumental in bringing Pathway to Cures into reality. Pathway to Cures is the venture philanthropy fund of the NBDF focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.

Pathway to Cures (P2C) held its inaugural fund meeting on Saturday, October 28th in Chicago, Illinois. Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation (NBDF), is a venture philanthropy fund focused on investing in early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.

Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders. Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.

Pathway to Cures (P2C), the venture philanthropy fund of the National Bleeding Disorders Foundation, focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community, announces a transformational gift to their fund.

Pathway to Cures (P2C) announced today its inaugural investment of $250,000 in Anvesana to develop therapies for treating inheritable blood and bleeding disorders. Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.

Pathway to Cures (P2C), a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community, has named Katherine High, MD; Haiyan Jiang, PhD; Glenn Pierce, MD, PhD and Steven Pipe, MD, to its Scientific Advisory Group. Leonard Valentino, MD, P2C’s Chief Executive Officer and NHF President and CEO, also serves on the Scientific Advisory Group.

Pathway to Cures (P2C), a venture philanthropy fund focused on transformative treatments for inheritable blood disorders, announces the appointment of its investment committee.